New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2013
15:39 EDTAVEOSectoral Asset Management reports 10.3% passive stake in Aveo Pharmaceuticals
News For AVEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 6, 2015
06:59 EDTAVEOAveo Pharmaceuticals to host conference call
Conference call to discuss final results and biomarker analysis from phase 2 study of Tivozanib will be held on March 6 at 8 am. Webcast Link
06:07 EDTAVEOAveo Pharmaceuticals reports Q4 EPS (27c), consensus (21c)
Reports Q4 revenue $115K, consensus $3.25M
06:06 EDTAVEOAveo Pharmaceuticals announces results from BATON-CRC study
AVEO Oncology announced the presentation of final results, including a predefined biomarker analysis, from the BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer. The BATON-CRC study enrolled a total of 265 patients randomized 2 to 1 to receive tivozanib in combination with mFOLFOX6 compared to bevacizumab and mFOLFOX6 as first-line treatment in patients with advanced metastatic CRC. A key objective of the BATON-CRC study is the assessment of prospectively defined biomarkers that may be predictive of response in selected patient subpopulations. Among these, patients with low neuropilin-1 showed an improved progression free survival versus patients with high NRP-1 in both treatment arms, supporting the value of NRP-1 as a potential prognostic marker for angiogenesis inhibitors. Further, patients with serum NRP-1 levels below the median demonstrated longer PFS when treated with tivozanib, compared to bevacizumab, suggesting NRP-1 may have potential as a predictive biomarker of tivozanib activity relative to bevacizumab. Patients with high serum NRP-1 had PFS of 7.3 months and 7.5 months for the tivozanib and bevacizumab arms, respectively. With only 21 deaths in the NRP-1 low group upon study termination, no conclusion could be reached in an analysis of overall survival. An earlier, pre-specified interim futility analysis determined that tivozanib was unlikely to demonstrate superiority to bevacizumab in the primary endpoint of PFS in the intent to treat population, resulting in discontinuation of the study. The results presented today are the final results, and include five additional months of study conduct and patient follow-up beyond the data cutoff for the interim futility analysis. In the intent to treat population, the tivozanib and bevacizumab combinations demonstrated comparable results for PFS, the primary endpoint, and overall response rate, while demonstrating comparable safety. The most common toxicities included diarrhea, nausea, fatigue, neutropenia and hypertension. Serious adverse events were reported for 46.3% of patients in the tivozanib group and 48.3% in the bevacizumab group.
February 27, 2015
07:14 EDTAVEOAveo Pharmaceuticals to host conference call
Conference call to discuss presentation of final results and biomarker analysis from Phase 2 study of Tivozanib in Patients with Advanced Colorectal Cancer will be held on March 6 at 8 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use